Ithaca, NY — July 22, 2010 — Rheonix, Inc. today announced that data demonstrating the utility of the Rheonix CARD™ (Chemistry And Reagent Device) system for human in vitro diagnostic purposes will be presented in poster sessions at the American Association for Clinical Chemistry (AACC) Annual Meeting being held in Anaheim, CA, July 25-29, 2010. Rheonix will also exhibit at the Clinical Lab Expo, Booth #1432.
The Rheonix CARD™ system is designed to meet the need for simple instrumentation that can perform a broad range of new or existing molecular diagnostic assays. Rheonix technology incorporates disposable microfluidic chip technology and a scalable automated platform to analyze single or multiple clinical raw samples, providing multiplexed endpoint analysis for a wide breadth of diagnostic applications.
Rheonix Presentations at AACC: Wednesday, July 28, 2:00 PM - 4:30 PM Pacific Time
• Session 14, Presentation number D-09, “Fully Integrated, Automatic, and Rapid Molecular Detection and Identification of 20 Clinically Relevant HPV types using the CARD™ Platform”
• Session 14, Presentation number D-10, “CARD™ Technology for Rapid and Automatic Determination of SNP Profile for Pharmacogenomics”
Thursday, July 29, 9:00 AM - 12:00 PM Pacific Time
• Session 20, Presentation number E-05, “Rapid Molecular Detection of Sexually Transmitted Infections using a fully automated, microfluidic CARD™”
About the Rheonix CARD™ System
The Rheonix CARD™ (Chemistry And Reagent Device) system allows sophisticated molecular and/or immunologic assays to be integrated into a simple, modular platform with unprecedented raw sample preparation capabilities and broad, multiplex analysis applications. This technology is extremely versatile and outperforms its labor-intensive “bench-top” counterparts. Disposable Rheonix CARD technology can be customized for immunoassay, pathogen identification, gene sequence detection, cell based assays and other molecular diagnostic applications. Rheonix CARD system advantages include:
• Virtually no hands-on effort, resulting in significantly reduced labor costs • Reduced sample volumes and reagent volumes, saving time and money • Performance of sophisticated assays through a series of programmable, automatic steps • Integrated biosensors, which enable a highly-sensitive assay with digital readout of results on the completely disposable microfluidic Rheonix CARD technology • Low-cost, scalable and reproducible manufacturing capabilities
To learn more about the Rheonix CARD system and its applications, please visit www.rheonix.com.
About Rheonix, Inc.
Rheonix has created a powerful microfluidic platform for the evolving molecular diagnostics industry. This system incorporates low-cost disposable Rheonix CARD™ technology to analyze single or multiple clinical raw samples. The Rheonix CARD system provides multiplexed endpoint analysis and can be rapidly customized for a wide breadth of diagnostic applications. www.rheonix.com
Contacts:
Rheonix, Inc.: Tony Eisenhut, President/CEO 607-257-1242, ext. 160
Media Contact: Douglas MacDougall or Jacqui Miller MacDougall Biomedical Communications 781-235-3060
